Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy
Autor: | Anders Jakobsen, Karina Dahl Steffensen, Jon Røikjær Henriksen, Parvin Adimi, Marianne Waldstrøm, Frede Donskov, Line Nederby |
---|---|
Rok vydání: | 2020 |
Předmět: |
Male
0301 basic medicine Oncology medicine.medical_specialty Multivariate analysis Neutrophils T-Lymphocytes medicine.medical_treatment Lymphocyte T cells lcsh:Gynecology and obstetrics NLR 03 medical and health sciences 0302 clinical medicine Immune system Ovarian cancer Internal medicine medicine Humans Lymphocytes Prospective Studies lcsh:RG1-991 Aged Aged 80 and over Ovarian Neoplasms B cells B-Lymphocytes Chemotherapy Performance status Platinum sensitivity business.industry Research Obstetrics and Gynecology Middle Aged Prognosis medicine.disease 030104 developmental biology medicine.anatomical_structure Recurrent Ovarian Cancer 030220 oncology & carcinogenesis Female Neoplasm Recurrence Local business |
Zdroj: | Journal of Ovarian Research Henriksen, J R, Nederby, L, Donskov, F, Waldstrøm, M, Adimi, P, Jakobsen, A & Steffensen, K D 2020, ' Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy ', Journal of Ovarian Research, vol. 13, no. 1, 59 . https://doi.org/10.1186/s13048-020-00661-4 Henriksen, J R, Nederby, L, Donskov, F, Waldstrøm, M, Adimi, P, Jakobsen, A & Steffensen, K D 2020, ' Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy ', Journal of Ovarian Research, vol. 13, 59 . https://doi.org/10.1186/s13048-020-00661-4 Journal of Ovarian Research, Vol 13, Iss 1, Pp 1-9 (2020) |
ISSN: | 1757-2215 |
DOI: | 10.1186/s13048-020-00661-4 |
Popis: | Purpose Biomarkers are needed to guide treatment decisions in recurrent ovarian cancer, as a high proportion of patients do not benefit from treatments. Data on immune subsets in patients receiving chemotherapy are scarce. We investigated the impact of T cells, B cells, neutrophils and the neutrophil-lymphocyte ratio (NLR) in ovarian cancer patients receiving palliative chemotherapy. Methods Blood samples were collected prospectively at baseline in recurrent ovarian cancer (N = 72) receiving chemotherapy. T cells, B cells, neutrophils, and NLR were analyzed. Primary and secondary endpoints were overall survival (OS) and treatment response, respectively. Cut-offs for T and B cells were predefined. Results In patients with low vs. high T and B cells counts, OS was 6.1 months vs 12.0 months (P = 0.017) and 6.1 months vs 12.0 months (P = 0.011, respectively. Low T and B cells analyzed as continuous variables were also associated with unfavorable OS, P = 0.011 and P = 0.007, respectively. Neutrophils had no significant prognostic impact. Median NLR was 4.1. High vs. low NLR was associated with poor survival, 7.4 months vs. 15.9 months (P = 0.012). In multivariate analysis including platinum sensitivity, number of prior lines of chemotherapy, and performance status, high NLR remained an independent poor prognostic factor HR: 2.17 (95% CI 1.21–3.88) (P = 0.009). High NLR was also significantly associated with lack of response, OR 0.15 (95% CI: 0.04–0.51) (P = 0.002). Conclusion In recurrent ovarian cancer patients undergoing palliative chemotherapy, low T and B lymphocyte counts had an unfavorable prognostic impact. High NLR was associated with lack of response and a poor prognosis, and the parameter may be used in patient counselling and treatment decisions. |
Databáze: | OpenAIRE |
Externí odkaz: |